BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new clinical data from the PEG-SN38 Phase 1 study evaluating heavily pretreated patients with solid tumors and lymphoma; and the recombinant human Mannose-Binding Lectin (rhMBL) clinical study for the replacement of MBL in patients with multiple myeloma undergoing high dose chemotherapy and hematopoietic stem cell transplantation. Data will be presented at the 2008 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.
